Dec 10, 2014 7:00am EST Immunovaccine Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer
Nov 19, 2014 8:05am EST Health Canada Clears Immunovaccine to Conduct Phase II Clinical Trial of DPX-Survivac in Recurrent Lymphoma
Nov 14, 2014 4:39pm EST Immunovaccine Announces Financial Results for Quarter Ended September 30, 2014
Nov 12, 2014 8:05am EST Immunovaccine Receives Conditional Approval to Graduate to Toronto Stock Exchange (TSX)
Oct 21, 2014 8:05am EDT Immunovaccine Demonstrates Protection Against Lethal Anthrax Challenge With Rapid Acting, Single Dose Vaccine
Oct 06, 2014 8:05am EDT Immunovaccine to Provide Update on Ongoing Ebola Virus and Cancer Vaccine Programs at 13th Annual BIO Investor Forum
Oct 01, 2014 8:05am EDT Immunovaccine Announces Plans for Phase II Clinical Trial of DPX-Survivac in Patients with Recurrent Lymphoma
Sep 26, 2014 8:05am EDT Immunovaccine Adds Broad Business Operations and Capital Raising Expertise to Board of Directors with New Appointments